source
- Eli Lilly to acquire AtaiBeckley for $2.8 billion, signaling deeper bet on psychedelicsEli Lilly announced on Thursday that it will acquire psychedelic drug developer AtaiBeckley. The purchase price is set at $2.8 billion paid upfront. The sizable upfront payment highlights Lilly's…
- Cue Biopharma appoints Dominic Borie as chief medical officer and head of R&DCue Biopharma announced the hiring of Dr. Dominic Borie, MD, PhD, as its new chief medical officer and head of research and development. Borie joins from Kyverna Therapeutics, where he served as a…